Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
29 March 2022 DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.
6 June 2022 Biotech company Illumina has asked a Delaware court to overturn a finding that it willfully infringed two DNA sequencing patents and must pay $334 million in damages.
29 March 2022 DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.
6 June 2022 Biotech company Illumina has asked a Delaware court to overturn a finding that it willfully infringed two DNA sequencing patents and must pay $334 million in damages.
29 March 2022 DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.
6 June 2022 Biotech company Illumina has asked a Delaware court to overturn a finding that it willfully infringed two DNA sequencing patents and must pay $334 million in damages.
